Sepsis is a clinical syndrome characterized by a dysregulated response to infection. It represents a leading cause of mortality in ICU patients worldwide. Although sepsis is in the point of interest of research for several decades, its clinical management and patient survival are improving slowly. Monitoring of the biomarkers and their combinations could help in early diagnosis, estimation of prognosis and patient's stratification and response to the treatment. Circulating soluble endoglin (sEng) is the cleaved extracellular part of transmembrane glycoprotein endoglin. As a biomarker, sEng has been tested in several pathologic conditions where its elevation was associated with endothelial dysfunction. In this study we have tested the ability of sEng to predict mortality and its correlation with other clinical characteristics in the cohort of septic shock patients (n = 37) and patients with severe COVID-19 (n = 40). In patients with COVID-19 sEng did not predict mortality or correlate with markers of organ dysfunction. In contrast, in septic shock the level of sEng was significantly higher in patients with early mortality (p = 0.019; AUC = 0.801). Moreover, sEng levels correlated with signs of circulatory failure (required dose of noradrenalin and lactate levels; p = 0.002 and 0.016, respectively). The predominant clinical problem in patients with COVID-19 was ARDS, and although they often showed signs of other organ dysfunction, circulatory failure was exceptional. This potentially explains the difference between sEng levels in COVID-19 and septic shock. In conclusion, we have confirmed that sEng may reflect the extent of the circulatory failure in septic shock patients and thus could be potentially used for the early identification of patients with the highest degree of endothelial dysfunction who would benefit from endothelium-targeted individualized therapy.

Department of Anesthesiology and Intensive Care St Anne's University Hospital Brno Czechia

Department of Cardiology University Hospital Brno Brno Czechia

Department of Modern Immunotherapy Research Institute of Hematology and Blood Transfusion Prague Czechia

Faculty of Medicine Masaryk University Brno Czechia

International Clinical Research Center St Anne's University Hospital Brno Czechia

Zobrazit více v PubMed

Singer M, Deutschman CS, Seymour C, Shankar-Hari M, Annane D, Bauer M, et al. . The third international consensus definitions for sepsis and septic shock (sepsis-3). J Am Medical Assoc. (2016) 315:801–10. 10.1001/jama.2016.0287 PubMed DOI PMC

Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent J-L. Sepsis and septic shock. Nat Rev Dis Prim. (2016) 2:16045. 10.1038/nrdp.2016.45 PubMed DOI PMC

Huang M, Cai S, Su J. The pathogenesis of sepsis and potential therapeutic targets. Int J Mol Sci. (2019) 20:215376. 10.3390/ijms20215376 PubMed DOI PMC

Hortová-Kohoutková M, Tidu F, de Zuani M, Šrámek V, Helán M, Frič J. Phagocytosis-inflammation crosstalk in sepsis: new avenues for therapeutic intervention. Shock. (2020) 54:606–14. 10.1097/SHK.0000000000001541 PubMed DOI PMC

Stanski NL, Wong HR. Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol. (2020) 16:20–31. 10.1038/s41581-019-0199-3 PubMed DOI PMC

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. J Am Medical Assoc. (2020) 323:1239–42. 10.1001/jama.2020.2648 PubMed DOI

Shoaib N, Noureen N, Munir R, Shah FA, Ishtiaq N, Jamil N, et al. . COVID-19 severity: Studying the clinical and demographic risk factors for adverse outcomes. PLoS ONE. (2021) 16:1–10. 10.1371/journal.pone.0255999 PubMed DOI PMC

Evans PC, Ed Rainger G, Mason JC, Guzik TJ, Osto E, Stamataki Z, et al. . Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc Res. (2020) 116:2177–84. 10.1093/cvr/cvaa230 PubMed DOI PMC

Lin GL, McGinley JP, Drysdale SB, Pollard AJ. Epidemiology and immune pathogenesis of viral sepsis. Front Immunol. (2018) 9:1–21. 10.3389/fimmu.2018.02147 PubMed DOI PMC

Koçak Tufan Z, Kayaaslan B, Mer M. COVID-19 and Sepsis. Turk J Med Sci. (2021) 51:3301–11. 10.3906/sag-2108-239 PubMed DOI PMC

de Zuani M, Lazničková P, Tomašková V, Dvončová M, Forte G, Stokin GB, et al. . High CD4-to-CD8 ratio identifies an at-risk population susceptible to lethal COVID-19. Scand J Immunol. (2021) 2021:1–11. 10.1111/sji.13125 PubMed DOI PMC

Rossi E, Bernabeu C, Smadja DM. Endoglin as an adhesion molecule in mature and progenitor endothelial cells: a function beyond TGF-β. Frontiers in Medicine. (2019) 6:1–8. 10.3389/fmed.2019.00010 PubMed DOI PMC

Quackenbush EJ, Letarte M. Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies. J Immunol. (1985) 134:1276–85. PubMed

Meurer SK, Weiskirchen R. Endoglin: an ‘accessory' receptor regulating blood cell development and inflammation. Int J Mol Sci. (2020) 21:1–28. 10.3390/ijms21239247 PubMed DOI PMC

Rossi E, Sanz-Rodriguez F, Eleno N, Düwell A, Blanco FJ, Langa C, et al. . Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration. Blood. (2013) 121:403–15. 10.1182/blood-2012-06-435347 PubMed DOI

Chen CZ, Li M, de Graaf D, Monti S, Göttgens B, Sanchez MJ, et al. . Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc Natl Acad Sci USA. (2002) 99:15468–73. 10.1073/pnas.202614899 PubMed DOI PMC

Droege F, Thangavelu K, Stuck BA, Stang A, Lang S, Geisthoff U. Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia. Vasc Med. (2018) 23:377–83. 10.1177/1358863X18767761 PubMed DOI

Gallardo-Vara E, Blanco FJ, Roqué M, Friedman SL, Suzuki T, Botella LM, et al. . Transcription factor KLF6 upregulates expression of metalloprotease MMP14 and subsequent release of soluble endoglin during vascular injury. Angiogenesis. (2016) 19:155–71. 10.1007/s10456-016-9495-8 PubMed DOI PMC

Ruiz-Llorente L, Vega MC, Fernández FJ, Langa C, Morrell NW, Upton PD, et al. . Generation of a soluble form of human endoglin fused to green fluorescent protein. Int J Mol Sci. (2021) 22:1–13. 10.3390/ijms222011282 PubMed DOI PMC

Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. . Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. (2006) 12:642–9. 10.1038/nm1429 PubMed DOI

Hawinkels LJAC, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, et al. . Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res. (2010) 70:4141–50. 10.1158/0008-5472.CAN-09-4466 PubMed DOI

Varejckova M, Gallardo-Vara E, Vicen M, Vitverova B, Fikrova P, Dolezelova E, et al. . Soluble endoglin modulates the pro-inflammatory mediators NF-κB and IL-6 in cultured human endothelial cells. Life Sci. (2017) 175:52–60. 10.1016/j.lfs.2017.03.014 PubMed DOI

Vicen M, Vitverova B, Havelek R, Blazickova K, Machacek M, Rathouska J, et al. . Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. FASEB J. (2019) 33:6099–114. 10.1096/fj.201802245R PubMed DOI

Rathouska J, Jezkova K, Nemeckova I, Nachtigal P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis. (2015) 243:383–8. 10.1016/j.atherosclerosis.2015.10.003 PubMed DOI

Helan M, Malaska J, Tomandl J, Jarkovsky J, Helanova K, Benesova K, et al. . Kinetics of biomarkers of oxidative stress in septic shock: a pilot study. Antioxidants. (2022) 11:1–12. 10.3390/antiox11040640 PubMed DOI PMC

Vieceli Dalla Sega F, Fortini F, Spadaro S, Ronzoni L, Zucchetti O, Manfrini M, et al. . Time course of endothelial dysfunction markers and mortality in COVID-19 patients: a pilot study. Clin Transl Med. (2021) 11:2020. 10.1002/ctm2.283 PubMed DOI PMC

Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. . Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. (2021) 49:5357. 10.1097/CCM.0000000000005357 PubMed DOI

Dolmatova E, Wang K, Mandavilli R, Griendling KK. The effects of sepsis on endothelium and clinical implications. Cardiovasc Res. (2021) 117:60–73. 10.1093/cvr/cvaa070 PubMed DOI PMC

Faiotto VB, Franci D, Enz Hubert RM, de Souza GR, Fiusa MML, Hounkpe BW, et al. . Circulating levels of the angiogenesis mediators endoglin, HB-EGF, BMP-9 and FGF-2 in patients with severe sepsis and septic shock. J Crit Care. (2017) 42:162–7. 10.1016/j.jcrc.2017.07.034 PubMed DOI

Lee SM, Kim SE, Kim E, Jeong HJ, Son YK, An WS. Lactate clearance and vasopressor seem to be predictors for mortality in severe sepsis patients with lactic acidosis supplementing sodium bicarbonate: a retrospective analysis. PLoS ONE. (2015) 10:1–14. 10.1371/journal.pone.0145181 PubMed DOI PMC

Iepsen UW, Plovsing RR, Tjelle K, Foss NB, Meyhoff CS, Ryrsø CK, et al. . The role of lactate in sepsis and COVID-19: perspective from contracting skeletal muscle metabolism. Exp Physiol. (2021) 2021:1–9. 10.1113/EP089474 PubMed DOI PMC

Andrianto, Al-Farabi MJ, Nugraha RA, Marsudi BA, Azmi Y. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Microvasc Res. (2021) 138:104224. 10.1016/j.mvr.2021.104224 PubMed DOI PMC

Tual-Chalot S, Garcia-Collado M, Redgrave RE, Singh E, Davison B, Park C, et al. . Loss of endothelial endoglin promotes high-output heart failure through peripheral arteriovenous shunting driven by VEGF signaling. Circul Res. (2020) 2020:243–57. 10.1161/CIRCRESAHA.119.315974 PubMed DOI PMC

Kapur NK, Heffernan KS, Yunis AA, Parpos P, Kiernan MS, Sahasrabudhe NA, et al. . Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. Am J Cardiol. (2010) 106:1770–6. 10.1016/j.amjcard.2010.08.018 PubMed DOI PMC

Li C, Hampson I, Hampson L, Kumar Pat, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor βl on human vascular endothelial cells. FASEB J. (2000) 14:55–64. 10.1096/fasebj.14.1.55 PubMed DOI

Hannan NJ, Brownfoot FC, Cannon P, Deo M, Beard S, Nguyen T, et al. . Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment. Sci Rep. (2017) 7:1–13. 10.1038/s41598-017-01993-w PubMed DOI PMC

Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry LJ, et al. . Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstetr Gynecol. (2016) 214:356.e1–15. 10.1016/j.ajog.2015.12.019 PubMed DOI

Hassan FI, Didari T, Khan F, Niaz K, Mojtahedzadeh M, Abdollahi M, et al. . Review on the protective effects of metformin in sepsis-induced organ failure. Cell J. (2020) 21:363–70. 10.22074/cellj.2020.6286 PubMed DOI PMC

Li J, Zeng X, Yang F, Wang L, Luo X, Liu R, et al. . Resveratrol: potential application in sepsis. Front Pharmacol. (2022) 13:1–10. 10.3389/fphar.2022.821358 PubMed DOI PMC

Vicen M, Igreja Sá IC, Tripská K, Vitverová B, Najmanová I, Eissazadeh S, et al. . Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome. Cell Mol Life Sci. (2021) 78:2405–18. 10.1007/s00018-020-03701-w PubMed DOI PMC

Rashad NM, Amin AI, Ali AE, Soliman MH. Influence of obesity on soluble endoglin and transforming growth factor β1 in women with polycystic ovary syndrome. Middle East Fertil Soc J. (2018) 23:418–24. 10.1016/j.mefs.2018.07.003 DOI

Fujita K, Ujike T, Nagahara A, Uemura M, Tanigawa G, Shimazu K, et al. . Endoglin expression in upper urinary tract urothelial carcinoma is associated with intravesical recurrence after radical nephroureterectomy. Int J Urol. (2015) 22:463–7. 10.1111/iju.12719 PubMed DOI

Abe T, Ogura H, Kushimoto S, Shiraishi A, Sugiyama T, Deshpande GA, et al. . Variations in infection sites and mortality rates among patients in intensive care units with severe sepsis and septic shock in Japan. J Intensive Care. (2019) 7:1–9. 10.1186/s40560-019-0383-3 PubMed DOI PMC

Leite AR, Borges-Canha M, Cardoso R, Neves JS, Castro-Ferreira R, Leite-Moreira A. Novel biomarkers for evaluation of endothelial dysfunction. Angiology. (2020) 71:397–410. 10.1177/0003319720903586 PubMed DOI

Vincent J-L, Ince C, Pickkers P. Endothelial dysfunction: a therapeutic target in bacterial sepsis? Expert Opin Ther Targets. (2021) 25:733–48. 10.1080/14728222.2021.1988928 PubMed DOI